Who
Marella Thorell
Officer
Company insider
Files Form 4 as: Officer, Seres Therapeutics; Director, ESSA Pharma; Director, Carisma Therapeutics; Chief Financial Officer, Evelo Biosciences; Director, GRI Bio; Chief Accounting Officer, Centessa Pharmaceuticals.
In numbers
- Trades disclosed
- 38
- Buys
- 1
- Sells
- 4
- Bought
- $20K
- Sold
- $26K
- Companies
- 6
- Companies where not an officer
- 3
- First trade
- 11 Dec 2020
- Last trade
- 8 Jul 2026
- Last filed
- 10 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jul 2026filed 10 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 9 Oct 2025filed 15 Oct 2025 | ESSA Pharma | SEC FORM 4 Code D | —2,881 | filing |
| 7 Feb 2025filed 11 Feb 2025 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | Carisma Therapeuticsoption or derivative | SEC FORM 4 Code A | —38,700 at $0.00 | filing |
| 25 Mar 2024filed 28 Mar 2024 | ESSA Pharmaoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 25 Mar 2024filed 27 Mar 2024 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
| 8 Nov 2023filed 8 Nov 2023 | Evelo Biosciences | SEC FORM 4 Sold | $5981,811 at $0.33 | filing |
| 7 Nov 2023filed 8 Nov 2023 | Evelo Biosciencesoption or derivative | SEC FORM 4 Code M | —6,500 at $0.00 | filing |
| 7 Nov 2023filed 8 Nov 2023 | Evelo Biosciences | SEC FORM 4 Code M | —6,500 | filing |
| 2 Nov 2023filed 3 Nov 2023 | Evelo Biosciences | SEC FORM 4 Sold | $1,3203,999 at $0.33 | filing |
| 1 Nov 2023filed 3 Nov 2023 | Evelo Biosciencesoption or derivative | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 1 Nov 2023filed 3 Nov 2023 | Evelo Biosciences | SEC FORM 4 Code M | —12,500 | filing |
| 11 Sep 2023filed 13 Sep 2023 | Evelo Biosciencesoption or derivative | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 8 Aug 2023filed 9 Aug 2023 | Evelo Biosciences | SEC FORM 4 Sold | $19K2,004 at $9.51 | filing |
| 7 Aug 2023filed 9 Aug 2023 | Evelo Biosciencesoption or derivative | SEC FORM 4 Code M | —6,500 at $0.00 | filing |
| 7 Aug 2023filed 9 Aug 2023 | Evelo Biosciences | SEC FORM 4 Code M | —6,500 | filing |
| 8 May 2023filed 10 May 2023 | Evelo Biosciences | SEC FORM 4 Sold | $5,00938,531 at $0.13 | filing |
News
No headline names them, or the companies they trade most, lately.